Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 7/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.50 |
| ▸ | HTR3B | O95264 | 4/20 | 0.50 |
| ▸ | HTR3A | P46098 | 4/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | HTR5A | P47898 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4467034 | 0.98 | ADRB1 (0.50) | ADRB1CMA1HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL5675045 | 0.98 | ADRB1 (0.50) | ADRB1CMA1HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL10755464 | 0.98 | ADRB1 (0.50) | ADRB1CMA1HTR3EHTR3BHTR3A | |
| SCHEMBL7503757 | 0.89 | TGFBR1 (0.55) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL10407803 | 0.88 | TGFBR1 (0.54) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8259247 | 0.86 | TGFBR1 (0.50) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5235512 | 0.83 | TGFBR1 (0.51) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL24434520 | 0.83 | CMA1 (0.56) | CMA1CYP3A4LMNAKMT2APOLB | |
| SCHEMBL16669473 | 0.82 | CYP1A2 (0.46) | ADRB1CMA1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11696465 | 0.81 | CMA1 (0.55) | CMA1CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | UNIV JOHNS HOPKINS (US) | 2026-04-02 | — | — | US | disclosed |
| US-12527746-B2 | Peptide/particle delivery systems | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4642434-A2 | LIPID COMPOSITIONS ON THE BASIS OF IONIZABLE LIPIDS, USE FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12458700-B2 | Amine-containing transfection reagents and methods for making and using same | Life Technologies Corporation (US) | 2025-11-04 | — | — | US | disclosed |
| US-12371522-B2 | Bioreducible poly (beta-amino ester)s for siRNA delivery | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250136737-A1 | MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS | THE JOHNS HOPKINS UNIVERSITY | 2025-05-01 | — | — | US | disclosed |
| CN-118742543-A | Dihydro isoquinoline compound and medical application thereof | 中国科学院上海药物研究所 | 2024-10-01 | — | — | CN | disclosed |
| US-20240263196-A1 | Lipid Compositions and Methods for Delivery to Immune Cells | Life Technologies Corporation | 2024-08-08 | — | — | US | disclosed |
| US-12049530-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERISTY (US) | 2024-07-30 | — | — | US | disclosed |
| EP-0313974-A1 | N-substituted derivatives of 1-desoxynojirimycine and 1-desoxymannonojirimycine, process for their preparation and their use as pharmaceuticals | BAYER AG (DE) | 1989-05-03 | — | — | EP | disclosed |
| US-4619932-A | CENTRAL NERVOUS SYSTEM CONTROLLERS; ANTI-SCHIZOPHRENIA AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-28 | — | — | US | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| US-4567187-A | CENTRAL NERVOUS SYSTEM | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-28 | — | — | US | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
| US-4460593-A | Carbostyril derivatives, and central nervous system controlling agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-07-17 | — | — | US | disclosed |
| US-4455422-A | ANTIHISTAMINES, CNS CONTROLLERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-19 | — | — | US | disclosed |
| US-4370330-A | Method of enhancing circulation with piperazines | MERZ & COMPANY (DE) | 1983-01-25 | — | — | US | disclosed |
| US-4370329-A | Piperazine derivatives as circulation-enhancing substances | MERZ & COMPANY (DE) | 1983-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527746-B2 | Peptide/particle delivery systems | VEGFA, IGF2BP2, MSTN | ADRB1 1326/4885CMA1 4651/4885HTR3E 1396/4885 |
| US-20250136737-A1 | MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS | PEF1, FIBP, PARN | ADRB1 4466/4885CMA1 875/4885HTR3E 1159/4885 |
| US-12458700-B2 | Amine-containing transfection reagents and methods for making and using same | SNRPA, NUDT21, SOAT2 | ADRB1 2390/4885CMA1 1881/4885HTR3E 2058/4885 |
| US-12371522-B2 | Bioreducible poly (beta-amino ester)s for siRNA delivery | AARS1, SLC43A1, PHAX | ADRB1 1085/4885CMA1 1780/4885HTR3E 3145/4885 |
| US-12049530-B2 | Multicomponent degradable cationic polymers | PEF1, FIBP, PARN | ADRB1 4466/4885CMA1 875/4885HTR3E 1159/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | ADRB1 2760/4885CMA1 959/4885HTR3E 2136/4885 |
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | SLC43A1, SLC7A5, SLC7A1 | ADRB1 961/4885CMA1 1069/4885HTR3E 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.